A detailed history of Nisa Investment Advisors, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 112 shares of PHAT stock, worth $1,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares
112
Previous 84 33.33%
Holding current value
$1,004
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$10.25 - $19.5 $287 - $546
28 Added 33.33%
112 $2,000
Q2 2024

Jul 19, 2024

BUY
$8.97 - $12.05 $574 - $771
64 Added 320.0%
84 $0
Q1 2024

May 01, 2024

SELL
$6.21 - $11.05 $62 - $110
-10 Reduced 33.33%
20 $0
Q4 2023

Jan 25, 2024

BUY
$6.99 - $10.71 $69 - $107
10 Added 50.0%
30 $0
Q2 2023

Aug 11, 2023

BUY
$7.28 - $14.32 $50 - $100
7 Added 53.85%
20 $0
Q4 2022

Feb 02, 2023

BUY
$9.18 - $11.53 $119 - $149
13 New
13 $0

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $351M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.